CXCL10 Impairs β Cell Function and Viability in Diabetes through TLR4 Signaling  by Schulthess, Fabienne T. et al.
Cell Metabolism
ArticleCXCL10 Impairs b Cell Function and Viability
in Diabetes through TLR4 Signaling
Fabienne T. Schulthess,1,2 Federico Paroni,2 Nadine S. Sauter,1 Luan Shu,1,2 Pascale Ribaux,3 Leena Haataja,1
Robert M. Strieter,4 Jose Oberholzer,5 Charles C. King,6 and Kathrin Maedler1,2,*
1Larry L. Hillblom Islet Research Center, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
2Centre for Biomolecular Interactions, University of Bremen, Bremen 28359, Germany
3Department of Genetic Medicine and Development, University Medical Center, Geneva 1211, Switzerland
4University of Virginia School of Medicine, Charlottesville, VA 22908, USA
5Division of Transplantation, University of Illinois at Chicago, Chicago, IL 60612, USA
6Department of Pediatrics, Center for Molecular Genetics, University of California, San Diego, La Jolla, CA 92093, USA
*Correspondence: kmaedler@uni-bremen.de
DOI 10.1016/j.cmet.2009.01.003SUMMARY
In type 1 and type 2 diabetes (T1/T2DM), b cell
destruction by apoptosis results in decreased b cell
mass and progression of the disease. In this study,
we found that the interferon g-inducible protein 10
plays an important role in triggering b cell destruc-
tion. Islets isolated frompatientswith T2DMsecreted
CXCL10 and contained 33.5-fold more CXCL10
mRNA than islets from control patients. Pancreatic
sections from obese nondiabetic individuals and
patients with T2DM and T1DM expressed CXCL10
in b cells.
Treatment of human islets with CXCL10 decreased
b cell viability, impaired insulin secretion, and
decreased insulinmRNA. CXCL10 induced sustained
activation of Akt, JNK, and cleavage of p21-activated
protein kinase 2 (PAK-2), switching Akt signals from
proliferation to apoptosis. These effects were not
mediated by the commonly known CXCL10 receptor
CXCR3 but through TLR4. Our data suggest CXCL10
as a binding partner for TLR4 and as a signal toward
b cell failure in diabetes.
INTRODUCTION
In both type 1 and type 2 diabetes (T1/T2DM), the major mech-
anism leading to the decreased b cell mass is increased b cell
apoptosis (Butler et al., 2003; Kurrer et al., 1997). A lack of pro-
liferation may be a reason for insufficient compensation for
a higher insulin demand in T2DM (Meier et al., 2008), e.g., under
the situation of obesity, pregnancy, or cortisol excess.
In T1DM, b cell destruction is mediated through the autoim-
mune system and the resulting high local concentrations of
inflammatory cytokines, chemokines, reactive oxygen species
(ROS), and other inflammatory products (Eizirik and Mandrup-
Poulsen, 2001). Several mechanisms have been postulated to
contribute to increased b cell apoptosis in T2DM. These include
endoplasmic reticulum (ER) stress, hyperglycemia, hyperlipid-
emia, oxidative stress, islet amyloid polypeptide (IAPP) oligo-Cemers, and activation of proinflammatory cytokines (Donath
et al., 2005).
The role of inflammation in the pathogenesis of T2DM is
supported by several recent prospective studies. Inflammatory
markers are found in obesity, insulin resistance, and diabetes
and link the pathology of the metabolic diseases (Wellen and
Hotamisligil, 2005). Low-grade inflammation and activation of
the innate immune system can lead to b cell failure in T2DM
(Pickup, 2004). Although the markers of immune activation are
below the levels of acute inflammation, there are increases in
acute phase proteins such as CRP and factors associated with
endothelial activation, including ICAM; VCAM and t-PA; cyto-
kines, e.g., IL-1b, IL-6, and TNFa; and chemokines, e.g., CCL5
(former RANTES), MCP-1, IL-8, and CXCL10 (Kolb and Man-
drup-Poulsen, 2005), which could directly lead to impaired
b cell survival and function, shown for cytokines in numerous
publications in vitro (Rabinovitch and Suarez-Pinzon, 1998).
The role of chemokines remains to be elucidated.
Interferon g-inducible protein (IP-10), also known as chemo-
kine (C-X-C motif) ligand 10 (CXCL10), is a 10 kDa secreted
protein produced in a variety of cells, including endothelial cells,
monocytes, fibroblasts, and keratinocytes (Luster, 1998).
Isolated human islets produce CXCL10 in response to IFN-g
(Cardozo et al., 2003). Increased levels of CXCL10 have been
detected in serum of patients with newly diagnosed as well
as longstanding T1DM (Nicoletti et al., 2002; Shimada et al.,
2001), T2DM (Xu et al., 2005), and in patientswith high risk for de-
veloping T1DM (Nicoletti et al., 2002) and T2DM (Giulietti et al.,
2006). In the nonobese diabetic (NOD) mouse model, CXCL10
is produced in pancreatic islets even before detectable insulitis
(Cardozo et al., 2003; Li et al., 2005). In a model of LCMV-
induced diabetes, CXCL10 has been shown to be among the first
chemoattractant factors expressed in the pancreas (Christen
and Von Herrath, 2004). These data suggest that upregulated
CXCL10 synthesis takes place either prior to or during an early
phase of the disease. Inhibition of CXCL10 delayed immune-
mediated diabetes in the NOD mouse (Morimoto et al., 2004),
and transgenic mice expressing CXCL10 in b cells show sponta-
neous infiltration of lymphocytes as well as impairment of b cell
function (Rhode et al., 2005). In mice deficient for the CXCL10
receptor CXCR3, T cell-mediated diabetes is substantially
delayed (Frigerio et al., 2002). Collectively, these studies implyll Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc. 125
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CXCL10 in Type 2 Diabetesthat CXCL10 is important in mediation of b cell apoptosis in
T1DM and a potential candidate in T2DM. In order to address
this possibility, we first posed the question of whether CXCL10
expression is increased in the islet in T1DM, in T2DM, or in
obesity. Having affirmed that postulate, we investigated whether
increased CXCL10 expression in the islet in T2DM is secondary
to most common metabolic milieus in T2DM, specifically
increased glucose or fatty acid concentrations. Because the
answer is negative, we further postulated that the expression
of CXCL10 may be a primary event in the evolution of b cell dys-
function in T2DM. Finally, we examined the effects of CXCL10 on
b cell function and viability in human islets and the underlying
mechanisms.
RESULTS
CXCL10 Is Expressed and Secreted in Isolated
Pancreatic Islets from Organ Donors with T2DM
Healthy human islets neither secreted nor expressed CXCL10
(Figures 1A and 1C, panel 1). In contrast, human isolated islets
from organ donors with T2DM secreted 65.62 ± 14.6 pg/ml/20
islets within 24 hr, which were accumulated after 96 hr (196 ±
58 pg/ml/20 islets; p < 0.001 versus control islets) (Figure 1A).
As a positive control for CXCL10 secretion, we incubated healthy
islets in the presence of the cytokine IFN-g (1000 U/ml). These
islets secreted 999.1 ± 127.2 pg/ml CXCL10/20 islets into the
culture medium during the 24 hr culture period.
The expression of CXCL10 mRNA by T2DM islets was
confirmed by quantitative RT-PCR. We found a 33.5-fold
increase of CXCL10 expression in the T2DM group (p < 0.01)
(Figure 1B). When we compared CXCL10 expression from islets
from lean and obese nondiabetic individuals, we found a small
but significant 3.3-fold increase in the obese islets (p < 0.05)
(Figure 1B). Islets were isolated from three organ donors with
diabetes (average HbA1c was 8.1, glucose was between 132
and 224 mg/dl, age was 60.7, and BMI was 27.2; cause of death
was subarachnoidal hemorrhage and stroke), from four obese
organ donors (average age was 48.5, and BMI was 34.3), and
from four lean control organ donors (average age was 54.3,
and BMI was 21.6).
Marselli et al. have compared several genes for their changes
during isolation by comparison of islets from laser capture
dissection and conventional islet isolation, and they found that
CXCL10 expression was unchanged by islet isolation (Marselli
et al., 2008). Therefore, it is unlikely that CXCL10 expression
was induced by the islet isolation.
We also investigated the islet cellular localization of CXCL10 in
pancreatic sections obtained at autopsy from seven poorly
controlled type 2 diabetic patients, all with documented fasting
plasma glucose > 145 mg/dl (see Table S1 available online for
age, gender, BMI, and glucose levels), as well as from one
pancreas biopsy obtained from a patient newly diagnosed with
T1DM (Meier et al., 2005). We have also included five autopsy
sections from obese and lean nondiabetic individuals. Double-
immunostaining for CXCL10 in red (Figure 1C, panels 1, 3, 5,
and 7) and insulin in green (Figure 1C, panels 2, 4, 6, and 8)
revealed the presence of CXCL10 localized in the b cells in hu-
man pancreatic sections from patients with T2DM (Figure 1C,
panels 5 and 6) and T1DM (Figure 1C, panels 7 and 8), but not126 Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inin lean nondiabetic controls (Figure 1C, panels 1 and 2). In con-
trast, in the nondiabetic obese controls, CXCL10-positive cells
were observed (Figure 1C, panels 3 and 4). The duration of
T2DM in the different patients ranged from 1 to 26 years, and
we did not detect differences in CXCL10 expression among
them. CXCL10 was absent in a cells, d cells, and exocrine cells.
Also, isolated human islets exposed to IFN-g stained positive for
CXCL10 (data not shown).
To investigate the processes that mediate CXCL10 expression
in vitro, human islets from nondiabetic organ donors were ex-
posed for 48 hr to a diabetic milieu (0.5 mM palmitate, 0.5 mM
palmitate plus 0.5 mM oleate, 2 ng/ml IL-1b, 1000 U/ml IFN-g
at 5.5 or 33.3 mM glucose) (Figure 1D, left panel), the combina-
tion of the three cytokines IL-1bplus IFN-gplus TNF-a (Figure 1D,
middle panel), or for 24 hr to 20 or 40 mM h-IAPP or 100 U/ml
TNF-a alone (Figure 1D, right panel). Western blot analysis
revealed that CXCL10 expression was independent of glucolipo-
toxicity or h-IAPP. CXCL10 expression was induced by TNF-
a and by IFN-g, confirming our RT-PCR and immunostaining
results (data not shown), and by the cytokine mixture IFN-g
plus IL-1b (Figure 1D, middle panel). Addition of TNF-a potenti-
ated CXCL10 expression induced by IFN-g plus IL-1b. In
contrast, elevated glucose levels did not further induce IFN-
g-induced CXCL10 expression (Figure 1D, lower panel).
CXCL10 Induces b Cell Death and Proliferation
and Impaired b Cell Function
To investigate the consequence of CXCL10 expression in human
type 2 diabetic islets, we added human recombinant CXCL10 to
cultured islets from healthy organ donors. We used 0.1 ng/ml
CXCL10, a concentration that we measured from islets from
donors with T2DM and that has been found in the serum from
patients with diabetes, aswell as 50 ng/ml, the ED50 for the ability
of CXCL10 to chemoattract T lymphocytes cultured in the pres-
ence of IL-2 (Loetscher et al., 1996).
Both 0.1 and 50 ng/ml CXCL10 increased b cell apoptosis by
1.6-fold ± 0.3-fold (n.s.) and 2.0-fold ± 0.4-fold (p < 0.01) after
1 day (data not shown) and 2.7-fold ± 0.5-fold and 2.9-fold ±
0.6-fold (p < 0.001) after 4 days of culture compared to untreated
control islets at 5.5 mM glucose (Figures 2A and 2C). After 1 day
of culture, CXCL10 showed a tendency to induce b cell prolifer-
ation (data not shown), which was significant after 4 days of
treatment (1.5-fold with 0.1 ng/ml and 2.7-fold with 50 ng/ml,
p < 0.05) compared to controls (Figures 2B and 2D). Basal apo-
ptosis and proliferation rates measured during the culture period
in control conditions did not change. To verify a specific
CXCL10-mediated effect and to exclude an endotoxin contami-
nation of the recombinant protein, we preincubated human
recombinant CXCL10 for 30 min with a neutralizing CXCL10
antibody and then exposed it to the islets. Treatment with anti-
CXCL10 Ab fully inhibited CXCL10-induced b cell apoptosis after
4 days (p < 0.001) compared to CXCL10-treated cells alone
(Figure 2C). Potential LPS contamination of the recombinant
CXCL10 was further investigated by preincubation of CXCL10
for 30 min at 37C in 5%CO2 with 2 mg/ml of polymyxin B, which
inhibits LPS (Giamarellos-Bourboulis et al., 2009). This did
not change CXCL10-mediated b cell apoptosis, confirming a
CXCL10-specific effect (b cell apoptosis was 2.5-fold induced
by CXCL10 pretreated with polymyxin, p < 0.0001).c.
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Figure 1. CXCL10 Is Increased in Islets from Patients with T2DM
(A) CXCL10 secretion from isolated human pancreatic islets from five healthy controls and three donors with T2DM.
(B) RT-PCR quantification of CXCL10 mRNA expression in human islets. Results represent means ± SE from four lean nondiabetic, four obese nondiabetic, and
three organ donors with T2DM.
(C) Double/triple-immunostaining in pancreatic tissue sections from a representative lean nondiabetic control (1 and 2), obese control (3 and 4), and a patient with
T2DM (5 and 6) or T1DM (7 and 8) (magnification, 3200).
(D) Human islets were cultured at 5.5 or 33.3 mM glucose for 48 hr (six experiments from six healthy organ donors). *p < 0.05 versus healthy untreated control
islets.We also show that, after 1 day culture in suspension dishes,
apoptosis is induced by CXCL10 using western blot analysis
of cleaved caspase 3 (Figure 3G). To confirm that CXCL10
actions were mediated by apoptosis and to investigate a matrix
independent effect, we quantified cleavage of caspase 3.
Human islets were cultured in suspension for 48 hr, Bouin’sCell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc. 127
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CXCL10 in Type 2 Diabetesfixed, and paraffin embedded, and islet sections were double-
stained for cleaved caspase 3 and insulin. CXCL10 induced
a 2.6-fold (p < 0.05) and 3-fold (p < 0.001) increase in caspase
3-positive b cells at 0.1 and 50 ng/ml CXCL10, respectively
(data not shown). In order to quantify b cell number after
CXCL10 exposure, we measured b cell viability in the b cell
line RINm5F and detected an 18% and 25% decrease in
viability by 0.1 and 50 ng/ml CXCL10, respectively (p < 0.01)
(Figure 2E).
Chronic preincubation of CXCL10 for 6 days induced a 48%
decrease in insulin stimulatory index (stimulated over basal insulin
secretion), compared tocontrol (p<0.05) (Figure2F). Todetermine
the acute effect ofCXCL10on insulin secretion,wecultured the is-
lets in the presence of CXCL10 at low and high glucose for 1 hr. At
low glucose, CXCL10 had no significant effect; however, at high
glucose,GSISwas 45%decreasedbyCXCL10compared to con-
trol (p <0.05), suggesting that the combinationof highglucose and
CXCL10, even in the short term, inhibits b cell function (Figure 2G).
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Figure 2. CXCL10 Induces b Cell Death and Impaired b Cell Function
(A–D) Human pancreatic islets cultured with increasing CXCL10 concentrations dishes for four days. Apoptosis wasmeasured by the TUNEL assay (A and C) and
proliferation by the Ki-67 antibody (B and D). Black arrows indicate doublets of apoptotic b cells indicative of postmitotic apoptosis (A3), and the red and black
arrows mark nuclei stained positive for Ki-67 (B).
(C and D) Human recombinant CXCL10 was preincubated for 30 min with an antagonistic CXCL10 antibody or polymyxinB and then incubated with the islets.
Results aremeans ± SE of TUNEL-positive (C) or Ki-67-positive (D) b cells per 1000 counted b cells (the average number of cells countedwas 4400 for TUNEL and
6358 for Ki-67 for each treatment group in each experiment) from four different experiments in triplicate from three to seven different organ donors.
(E) MTT was performed on RINm5F cells exposed for 4 days to CXCL10.
(F) GSIS from islets exposed to CXCL10. Basal and stimulated insulin secretion indicate the amount secreted during 1 hr incubations at 2.8 (basal) and 16.7 mM
(stimulated) glucose following the 6 day culture period and normalized to insulin content.
(G) Acute basal and stimulated insulin secretion for 1 hr, normalized to insulin content.
(H) Quantitative RT-PCR analysis of insulin expression. Total mRNA was isolated from human islets from three different organ donors and cultured for 1 day in
5.5 mM glucose with or without CXCL10.
Results are means ± SE of untreated controls at 5.5 mM glucose. *p < 0.05 to untreated control; +p < 0.05 to 2.8 mM glucose; #p < 0.05 to 0.1 ng/ml CXCL10.128 Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc.
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CXCL10 in Type 2 DiabetesFigure 3. Activation of the PI3K/Akt Pathway by CXCL10 Subsequently Leads to PAK-2 Cleavage and Apoptosis in b Cells
(A and B) Western blot analysis of p-Akt in human islets.
(C) Human islets were cultured for 4 days in 5.5 mM glucose. Results are mean ± SE of TUNEL-positive per 1000 b cells. *p < 0.05 relative to islets cultured at
5.5 mM glucose alone; +p < 0.05 relative to islets in the absence of Wortmannin at the same CXCL10 concentration.
(D–G) Western blot analysis of human islets cultured for 1 day or from 5min to 1 day (F) or from purified rat b cells (E). Heat shock-treated CHO cells were used as
a positive control for activated PAK-2p34 (E).
RepresentativeWestern blots from four independent experiments from four different organ donors (A, B, D, and F), two different donors (G), or three different b cell
isolations (E).Insulin content decreased by 46% in the CXCL10-treated cells
(0.01 ng/ml, p < 0.05) (data not shown). Insulin mRNA was
decreased by 52% and 56% after 1 day of culture by 0.1 and
50 ng/ml CXCL10, respectively (p < 0.05) (Figure 2H). We then
examined the effects of two other ligands of CXCR3—IFN-g-
inducible chemokines CXCL11 (former I-TAC) and CXCL9 (former
Mig)—on b cell turnover in human isolated islets. In contrast to
CXCL10, neither CXCL11 nor CXCL9 at comparable concentra-
tions, based on their activity, affected b cell apoptosis and b cell
proliferation (Figure S1A) after 4 days of culture. To investigate
a functional response induced by CXCL11 and CXCL9, the mobi-
lization of intracellular calcium was assessed by Fluo-3 in INS-1
cells. Both CXCL11 and CXCL9 induced the mobilization of
[Ca2+]i in the cells, which confirms their activity (Figure S1B). As
positive control for [Ca2+]i influx in the b cells, we used 20 mM
glucose, which also resulted in Fluo-3 uptake (data not shown).
CXCL10-Mediated PAK-2 Cleavage Switches Akt
Signaling into Apoptosis
Next,weexamined themolecularmechanismof thedeleterious ef-
fects of CXCL10 on cultured human islets. We detected increased
Akt phosphorylation within 30 min of culture with CXCL10, which
was sustained through the entire 24 hr culture period (Figures 3A
and 3B). The PI3K inhibitor Wortmannin (100 nM) blocked this
Akt phosphorylation in the presence of CXCL10, confirming that
PI3K signaling was involved (Figure 3A). Furthermore, PI3K inhibi-
tion blocked CXCL10-induced b cell death (Figure 3C). Here, we
show that sustained Akt activation can trigger apoptosis in the
b cell. One of the direct downstream effectors of Akt is the p21-ac-
tivated kinase 2 (PAK-2). Akt-mediated phosphorylation of PAK-2
mediates cell survival; however, if PAK-2 is proteolytically cleaved,
apoptosis is induced (Jakobi et al., 2003). We found full-length
PAK-2 constitutively expressed in human islets and rat b cells.
However, upon CXCL10-induced caspase 3 cleavage (Figure 3G
forhuman isletsand3E for ratbcells),wedetected increased levels
of the cleavedC-terminal fragment of PAK-2 (PAK-2p34) in human
islets and in purified rat b cells (Figures 3D and 3E). Heat-shocked
hamster ovary cells (CHO) were used as positive control for PAK-2
cleavage (Chanet al., 1998). Besides caspase 3 andPAK-2activa-
tion, CXCL10 also triggered JNK activation, a pathway that is
activated by inflammatory cytokines and free fatty acids in the
b cell, leading to b cell apoptosis (Hotamisligil, 2005).Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc. 129
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(Aikin et al., 2000), and proteolytic activation of PAK-2 correlated
with activation of JNK in previous reports (Rudel et al., 1998).
Therefore, we aimed to investigate the link of the CXCL10-acti-
vated pathways through JNK.
After 5 min of exposure, CXCL10 induced JNK activation that
still persisted after 1 day of culture (Figure 3F), which was similar
Figure 4. The Effects of CXCL10 Are CXCR3 Inde-
pendent
(A–D) Analysis of b cell apoptosis and function inCXCR3/
mice. Mouse islets were cultured on extracellular matrix-
coated dishes for 4 days.
(A and B) TUNEL assay.
(C) Basal and stimulated insulin secretion during 1 hr
incubation at 2.8 (basal) and 16.7 mM (stimulated) glucose
following a 4 day culture period.
(D and E) Isolated islets from C57BL/6J mice were
precultured for 1 hr with goat serum (control) or with goat
anti-mouse CXCR3 neutralizing antibody prior to addition
of 0.1 ng/ml recombinant mouse CXCL10.
Results are means ± SE of the percentage of TUNEL-
positive (B and D) and Ki-67-positive (E) b cells per 1000
b-cells. Results are means ± SE of two independent ex-
periments in quadruplicates from six mice, respectively.
*p < 0.05 to untreated control islets.
(F) RT-PCR for CXCR3was performed frompurified human
b cells and human islets cultured for 3 days.
(G) Immunohistochemical analysis for CXCR3 on sections
from human isolated islets. Magnification, 3200.
to the pattern of Akt activation. Using the small
molecule inhibitor of JNK (JNKi), we show that
JNK inhibition protected from CXCL10 induced
bcell apoptosis andPAK-2cleavage (Figure 3G).
This was confirmed by the costaining of human
islets with insulin and the TUNEL assay, in which
coculture of JNKi 30 min before exposure of the
human islets with CXCL10 significantly abol-
ished b cell apoptosis (data not shown).
The Effect of CXCL10 on b Cells Is
Independent of the CXCR3 Receptor
CXCL10 is the ligand for the receptor CXCR3. To
further study the mechanisms of CXCL10-
induced b cell destruction, we investigated the
role of its receptor, CXCR3. We exposed is-
lets isolated from CXCR3 knockout mice to
CXCL10. Similar to our observations in human
islets, CXCL10 induced b cell apoptosis in islets
from wild-type C57Bl/6J mice (Figure 4A).
Furthermore, we did not detect alterations of
CXCL10-induced increase in b cell death
(Figures 4A and 4B) and insulin secretion
(Figure 4C) in islets isolated from CXCR3 knock-
out mice (0.1 and 50 ng/ ml CXCL10 increased
b cell apoptosis 2.7-fold and 2.0-fold,
respectively; p < 0.05). By preincubation with
0.1 ng/ml CXCL10 for 6 days, glucose-stimu-
lated insulin secretion was decreased by 41%
and stimulatory index by 77% compared to untreated control
(p < 0.05).
Compared to human islets, the deleterious effect of chronic
CXCL10 pretreatment on GSIS was greater in mouse islets.
The stimulatory index under control conditions was higher in
mouse than in human islets (2.6 versus 6.9). This could be due
to different islet isolation procedures. Mouse islets were isolated130 Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc.
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human islets were shipped to our lab and had to be precultured
after shipment.
Then, we precultured isolated pancreatic islets from C57Bl/6J
mice with goat anti-mouse CXCR3, an antagonistic antibody to
CXCR3 that has been shown previously to block CXCL10-medi-
ated effects (Molesworth-Kenyon et al., 2005). After 1 hr precul-
ture, CXCL10was added to the islets for the 3 day culture period.
CXCL10 increased apoptosis 2.4-fold without and 2.6-fold with
CXCR3 neutralization compared to serum-treated control (p <
0.05) (Figure 4D). In parallel, proliferation was 1.7-fold increased
without and 1.6-fold increased with CXCR3 neutralization
compared to serum treated control (p < 0.05) (Figure 4E). There
were no differences between the treatment groups with or with-
out the neutralizing antibody.
Because CXCL10 exhibits similar effects in the presence and
absence of CXCR3, we assume that its effect is CXCR3 indepen-
dent in pancreatic b cells. Subsequently, we analyzed CXCR3
gene expression in human islets. CXCR3 mRNA was detected
in islets as well as in purified b cells (Figure 4F). Sequence
analysis of the PCR products confirmed CXCR3 expression
according to published sequences. By fluorescent immunocyto-
chemistry, we found CXCR3 expression in human islets (1.08 ±
0.16 positive cells/islet). We observed CXCR3-positive b cells
(Figure 4G, panels 1 and 2), but most CXCR3-positive cells
were negative for insulin. No CXCR3 staining was observed in
a and d cells, as assessed by double-immunostaining with
anti-glucagon or anti-somatostatin antibodies, respectively
(Figure 4G, panels 3–6). Synaptophysin and chromogranin A
(alternative markers for endocrine cells) only partially colocalized
with CXCR3 (data not shown). Because CXCR3 is expressed
in activated T cells, we performed triple staining for insulin
(Figure 4G, panel 7), CXCR3 (Figure 4G, panel 8), and a T cell
marker CD3 (Figure 4G, panel 9) and found CXCR3-positive
T cells in human islets. However, we detected a large variation
in the number of these CXCR3-positive b and T cells in the six
different human islet isolations studied. The expression levels
of CXCR3 in the islets were similar in untreated cells and cells
treated with CXCL10 or IL-1b and IFN-g (data not shown).
CXCL10 Binds to TLR4 in Pancreatic b Cells
and Mediates b Cell Apoptosis
In the search for the specific receptor for the CXCL10-mediated
effects in b cells, we analyzed gene expression of a number of
receptors in islets by PCR. Initially, we looked for GPR1 (a func-
tional CXCL10 receptor detected in epithelial and endothelial
cells [Soejima and Rollins, 2001]), CCR3 (CXCR3 ligands were
found to bind to CCR3 in T cells [Booth et al., 2002; Loetscher
et al., 2001] but exhibit antagonistic effects), CCR5 (which is
highly upregulated by TNF-a and IFN-g, together with upregula-
tion of CXCL10 [Croitoru-Lamoury et al., 2003]), and TLR4 (upon
its activation, CXCL10 production is induced). Untreated human
islets expressed all of the four receptors (Figure 5A). To identify
the binding capacity of CXCL10 to these receptors, we used
the Dynabead technology (Invitrogen). Beads were coated with
CXCL10 prior to incubation with human islet lysates. While
CCR5 and GPR1 failed to bind CXCL10 and CCR3 had a limited
capacity to bind CXCL10, we identified TLR4 as the receptor for
CXCL10 (Figure 5B).
To confirm the hypothesis that CXCL10 is a ligand for TLR4,
a classical radioactive receptor-binding assay has been per-
formed (Bernhagen et al., 2007). As cell models for the binding
assay, the HEK293 and the macrophage cell lines RAW 264.7
have been chosen. Whereas HEK293 cells completely lack
TLR4 (Erridge et al., 2007) as well as CXCR3 (Lu et al., 1999)
expression, TLR4 is constitutively expressed in RAW 264.7 cells
(Fang et al., 2004). The 293 cells were cotransfected with
a combination of expression constructs TLR4/MD2/CD14 in
order to reconstitute the complete receptor apparatus. For the
assay, we used a constant 1 nM concentration of 125I-labeled
CXCL10. The concentration of unlabeled competitor lipopoly-
saccharide (LPS), a well-known specific ligand for TLR4 (Pals-
son-McDermott and O’Neill, 2004), was between 0.1 ng/ml and
100 mg/ml, and the concentration of IFN-g as negative control
was between 10 and 1000 U/ml. CXCL10 was able to bind the
TLR4 receptor in the presence of MD2 and CD14 (Figure 5C)
and in the presence of MD2 alone (similar results; data not
shown), whereas CXCL10 binding did not occur in the presence
or absence of unlabeled LPS in either untransfected (Figure 5E)
or transfected 293 cells with only the vector expressing TLR4
(data not shown). Unlabeled LPS competed for the binding site
andwas able to displace radiolabeled CXCL10 at concentrations
higher than 50 mg/ml in both cell lines 293 (Figure 5C) and
RAW264.7 (Figure 5D). IFN-g as cold competitor was used under
the same experimental conditions and was unable to displace
hot CXCL10 from the binding site, confirming the specific inter-
action between CXCL10 and TLR4 (Figures 5C and 5D, insert).
The efficiency of transfection has been determined using a
GFP reporter plasmid, and the expression of the TLR4, MD2,
and CD14 has been confirmed by western blot analysis (data
not shown). We next examined the ability of CXCL10 to regulate
TLR4 receptor expression. An amount of 0.1 ng/ml CXCL10
caused a 2-fold induction of TLR4 mRNA (Figure 5F). Since
TLR4 signaling results in upregulation and secretion of CXCL10
(Giarratana et al., 2004; Hoshino et al., 2002; Selvarajoo, 2006),
we examined CXCL10 production downstream of CXCL10 sig-
naling and measured a 4.5-fold and 33.3-fold induction of
CXCL10 mRNA in human islets after treatment with 0.1 and
50 ng/ml CXCL10, respectively (Figure 5G). To investigate
whether CXCL10 signaling is TLR4 dependent, we exposed
human islets to a TLR4-specific siRNA (siTLR4) or scrambled
control siRNA (siScr). For evaluating transfection efficiency,
islets were treated with FITC-labeled nontargeted siRNA and
green fluorescence monitored over the 4 day culture period.
Transfection efficiency was 5% after 24 hr and 75% after
48 hr, which was maintained during the 4 day experiment (data
not shown).
We achieved an average downregulation of 48% TLR4 protein
expression by the siRNA, shown by western blot analysis
(Figure 5H, insert). After a 4 day culture period with 0.1 ng/ml
CXCL10, we analyzed b cell apoptosis. CXCL10 treatment
induced a 4-fold induction of b cell apoptosis in human islets
pretreated with scramble control siRNA (siSCR). Pretreatment
with siTLR4 induced a 39.6% reduction of b cell apoptosis (p <
0.05) (Figure 5H), supporting a specific involvement of TLR4 in
CXCL10 signaling.
TLR4, CD14, and MD2 are expressed in b cells (Vives-Pi et al.,
2003). This was confirmed in our study in isolated human isletsCell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc. 131
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CXCL10 in Type 2 DiabetesFigure 5. CXCL10 Binds to TLR4 in Pancreatic b Cells and Mediates b Cell Apoptosis
(A) PCR analysis of GPR1, CCR3, CCR5, and TLR4 in isolated human islets.
(B) Paramagnetic pull-down assay in human isolated islets. CXCL10 was bound to magnetic beads and incubated with human islet lysates. After magnetic
separation, the bead fraction, supernatants (output) together with the original islet fraction before the pull-down (input), was transferred to lysate buffers, and
western blot analysis was performed (three experiments from three different islet donors).
(C–E) Radioactive receptor-binding assaywas performed in 293 and RAW264.7 cell lines with 1 nM radioactive-labeled CXCL10 and increasing concentrations of
nonlabeled LPS.
(C) The 293 cells were cotransfected with different plasmids expressing TLR4, MD2, and CD14.
(D) Results of the RAW264.7 cells are shown. In both cases, the specificity of the binding is confirmed by the ability of increasing concentrations of cold-LPS to
displace CXCL10 from the binding site. Control for the specific interaction of CXCL10 and TLR4 has been confirmed using increasing concentrations of132 Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc.
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CXCL10 in Type 2 Diabetesby double-staining for insulin and TLR4, CD14, and MD2
(Figure 5I). We treated the islets with CXCL10 and detected
a slightly enhanced expression of TLR4 and an increased MD2
expression in the b cells. In contrast, CD14 was unchanged by
CXCL10.
We next investigated whether CXCL10-mediated TLR4 signal-
ing is linked to the activation of the Akt/PAK-2/JNK pathway by
western blot analysis. Addition of a neutralizing antibody against
CXCR3 changed neither CXCL10-induced PAK-2 cleavage nor
activation of JNK. In contrast, inhibition of TLR4 signaling by ad-
dition of a dominant-negative virus for myeloid differentiation pri-
mary response protein 88 (Myd88), a key adaptor molecule in
TLR4 signaling, prevented both CXCL10-induced PAK-2 cleav-
age and activation of JNK (Figures 5J and 5K). Also, blocking
Akt activation by two different PI3K inhibitors (Wortmannin and
LY294002) blocked PAK-2 cleavage as well as JNK activation,
which suggests that Akt is upstream of PAK and JNK and
confirms their interaction.
TLR4/ Mice Are Protected from the Diabetogenic
Effect of CXCL10
To further confirm the involvement of TLR4 in CXCL10-mediated
b cell destruction, we analyzed b cell apoptosis from islets iso-
lated from C57Bl/6 and TLR4/ mice (8 to 12 weeks old). We
used LPS as positive control to induce TLR4-dependent apopto-
sis, which induces b cell damage in vitro (Arnush et al., 1998) and
in vivo (Saitoh et al., 2004). In our study, 20 mg/ml LPS induced
a 2.9-fold induction of b cell apoptosis, which was prevented
in isolated islets from TLR4 knockout mice (data not shown).
CXCL10 exposure of the islets resulted in a 2.2-fold increase in
b cell apoptosis in the wild-type, but not in the TLR4/ mice
(Figure 6A). Since we have used C57Bl/10ScCr mice, which
were reported to have a mutation in the IL-12Rbeta2 chain in ad-
dition to TLR4 deletion (Poltorak et al., 2001), the TLR4-specific
effect was confirmed by overexpressing TLR4 in the TLR4/ is-
lets. Treatment of the TLR4/ with CXCL10 did not result in
caspase 3 activation. In contrast, when TLR4/ islets were
transfected with construct for mouse TLR4, CXCL10 induced
caspase 3 activation. Western blot analysis showed the absence
of TLR4 in the TLR4/mice and confirmed TLR4 plasmid over-
expression (Figure 6B). To answer the question of whether the
CXCL10 effects on b cells in vitro would also result in impaired
glucose homeostasis in vivo, we performed glucose tolerance
tests in 10-week-old WT and TLR4/ mice injected with 100
ng CXCL10 over 8 days. CXCL10 resulted in impaired fasting
glucose and elevated glucose levels 15, 30, and 60min after glu-Celcose injection (Figure 6C). In parallel, glucose-stimulated insulin
secretion was reduced by 39% (p < 0.05) (Figure 6D) in the
CXCL10-injected WT mice. Such effects were not observed in
the TLR4/ mice (Figures 6C and 6D). We posed the question
of whether islet survival was affected in vivo by CXCL10 injec-
tions. In line with our in vitro data, isolated WT mouse islets in-
jected with CXCL10 showed cleaved caspase 3 expression,
whereas it was neither detected in solvent-treated isolated islets
from WT mice nor in both solvent and CXCL10-treated TLR4/
mice (Figure 6E).
DISCUSSION
Cytokines and chemokines produced and secreted by activated
macrophages, adipocytes, and also by pancreatic b cells have
been suggested to initiate b cell apoptosis in T1DM and T2DM
(Donath et al., 2003). Understanding the mechanisms of secre-
tion and function of these proinflammatory factors is important
for the treatment of diabetes.
In the present study, we report that the chemokine CXCL10 is
produced and secreted by cultured human islets of patients with
T2DM. Immunostaining shows CXCL10 in pancreatic sections
from patients with T1 and T2DM predominantly localized in
b cells. Interestingly, we also could find some CXCL10 staining
in the islet sections from obese individuals. This is in line with
findings from a recent study that shows that CXCL10 is associ-
ated with both BMI and waist circumference (Herder et al.,
2007) and may provide a link from obesity to diabetes through
CXCL10 expression.
Elevated serum CXCL10 levels have been observed in T2DM
and are between 184 and 248 pg/ml (Herder et al., 2006; Xu
et al., 2005) and between 200 and 600 pg/ml in recent onset
type 1 diabetic patients (Nicoletti et al., 2002; Shimada et al.,
2001).
We found a similar CXCL10 concentration of 100 pg/ml se-
creted by isolated islets from donors with T2DM. An amount of
100 pg/ml CXCL10 induced an 3-fold induction of b apoptosis
in human andmouse islet isolations, which correlates with the in-
duction of apoptosis observed in vivo in pancreatic sections
from autopsy from patients with T2DM (Butler et al., 2003) as
well as with T1DM (Meier et al., 2005). We frequently observed
doublets of apoptotic b cells, indicative of postmitotic apoptosis,
supporting the concept that replicating b cells are more vulnera-
ble to apoptotic stimuli (Donath et al., 1999; Ritzel and Butler,
2003). A critical regulator of b cell proliferation and survival is
Akt (also known as protein kinase B [PKB]), which is activatednonlabeled IFN-g under the same experimental conditions, which did not compete for CXCL10 binding (inserts in [C and D]). As control, radioactivity was mea-
sured in cells treated with CXCL10 alone in RAW267.4 cells and in nontransfected 293 cells, where only background radioactivity was measured. The binding
activity has been calculated as centicounts per minute (CCPM).
(F and G) Quantitative RT-PCR was performed in human islets exposed to CXCL10 for 3 days. The increases in TLR4 (F) and CXCL10 (G) mRNA expression are
expressed as relative change from the untreated control (four experiments from four islet donors).
(H) Isolated human pancreatic islets were cultured on extracellular matrix-coated dishes and exposed to 50 nM scrambled control siRNA (siScr) or siRNA to TLR4
(siTLR4). At 1 day after transfection, CXCL10 was added, and apoptosis was measured by double-staining for TUNEL and insulin after the 4 day culture period.
Results are means ± SE of TUNEL-positive b cells per 1000 b cells. Western blot analysis of TLR4 shows 48% downregulation in the siTLR4-treated human islets
(insert).
(I) Islet sections were double-stained for insulin and TLR4 (left panel), CD14 (middle panel), and MD2 (right panel).
(J and K) Western blot analysis from human isolated islets after 24 hr exposure to 0.1 ng/ml CXCL10 with or without preincubation with an antagonistic CXCR3
antibody, 100 nM Wortmannin, 50 mM LY294002, or a dominant-negative virus for Myd88 (three independent experiments from three different organ donors).
*p < 0.05 to untreated control; **p < 0.05 to CXCL10 treated control islets.l Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc. 133
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CXCL10 in Type 2 Diabetesdownstream of PI3K (Aikin et al., 2000). In previous reports,
blocking Akt phosphorylation renders islets more susceptible
to b cell apoptosis (Dickson and Rhodes, 2004). Akt undoubtedly
plays an important role in regulating b cell growth and survival
(Bernal-Mizrachi et al., 2001; Tuttle et al., 2001). It is a convergent
point in cell signaling, i.e., induced by insulin and growth factors,
and is involved in the regulation of cell cycle by altering its com-
ponents, e.g., it increases protein stability of cyclin D and p21
(Fatrai et al., 2006). In contrast, CXCL10 induced apoptosis
despite upregulated p21 levels (Zhang et al., 2005).
We have observed a sustained Akt activation by CXCL10.
A similar role for Akt in promoting rather than preventing apopto-
sis has been shown before (Castino et al., 2008; Lu et al., 2006).
Administration of the PI3K inhibitor Wortmannin inhibited Akt
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Figure 6. TLR4/ Mice Are Protected from the Diabetogenic Effect of CXCL10
(A) Analysis of b cell apoptosis in wild-type and TLR4/ mice. Mouse islets were cultured for 4 days.
(B) Western Blot analysis of isolated islets from TLR4/mice transfected with an expression vector for LacZ (negative control) or mouse TLR4 and exposed to
0.1 ng/ml CXCL10 for 3 days.
(C–E) WT and TLR4/ mice (10 weeks old) were injected with 100 ng CXCL10 or solvent over 8 days.
(C and D) IPGTTs were performed at the end of the experiment, and (C) glucose levels were measured during 120 min. (D) Plasma insulin levels were measured
from the same mice during the IPGTT 30 min before and after glucose injection, expressed as stimulated (30 min) over basal (0 min) insulin secretion. Results
shown are the means ± SE (3 independent experiments with a total of 12 mice in each group). *p < 0.05 CXCL10 injected WT mice to untreated WT mice.
(E) Western blot analysis from isolated islets from the same mice.
(F) Our view on the pathways of CXCL10 in the b cell. Binding of CXCL10 to TLR-4 leads toMyD88-mediated long-term activation of Akt. Akt crosstalks with JNK,
and its activation leads to cleavage of caspase 3. The signal for proliferation is converted to apoptosis initiated by the cleavage of PAK2.134 Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc.
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CXCL10 in Type 2 Diabetesphosphorylation as well as CXCL10-induced b cell death,
suggesting that CXCL10 mediated its effects through sustained
Akt activation. The role of Akt in the maintenance of b cell mass
and survival has been debated recently. Mice carrying an 80%
depletion in Akt do not display loss of islet mass, in contrast to
the phenotype of IRS-2-deficient mice, which display a severe
b cell loss (Bernal-Mizrachi et al., 2004). Therefore, downstream
effectors of this signaling pathway may play a more critical role
than Akt activation itself. CXCL10-induced Akt activation may
first lead to proliferation and survival, but, at an event, when
b cells are highly vulnerable to apoptosis, it is finally switched
toward b cell death by other downstream signals. Among such
downstream targets of Akt are p21-activated kinases (PAK)
(Tang et al., 2000). PAKs are activated by a variety of GTPase-
dependent and independent mechanisms (Bokoch, 2003).
Among them, PAK-1 and PAK-2 regulate cell survival and apo-
ptosis. PAK-1 protects from apoptosis (Faure et al., 1997),
whereas PAK-2 has a unique dual function: activation of full-
length PAK-2 stimulates cell survival (Jakobi et al., 2001),
whereas, upon cleavage into a 34 kDa activated form (PAK-
2p34), it directs apoptosis (Rudel and Bokoch, 1997). Here, we
show the presence of the cleaved fragment PAK-2p34 upon
caspase 3 activation in b cells. Such proteolytic activation of
PAK-2 correlated with activation of the c-Jun amino terminal ki-
nase (JNK) in our study aswell as in previous reports (Rudel et al.,
1998). Similar to the pattern of Akt activation, we observed that
stimulation of human islets with CXCL10 elicits a prolonged ac-
tivation of JNK, and blocking JNK could inhibit cleavage of cas-
pase 3 and PAK-2 (a suggested mechanism of the Akt-JNK-
PAK2 pathway is summarized as a cartoon in Figure 6F).
CXCL10 exerts its biological activity through the G protein-
coupled receptor CXCR3. Also, CXCR3-independent effects of
CXCL10 have been described (Cole et al., 2001; Luster et al.,
1995; Soejima and Rollins, 2001). Our data support such
CXCR3-independent effects in pancreatic islets. First, CXCL10
exhibited similar effects on the b cells in the presence and ab-
sence/neutralization of CXCR3, and, second, two other known
CXCR3-binding chemokines, CXCL11 and CXCL9, did not affect
b cell turnover. The possible mechanism of a CXCR3-indepen-
dent CXCL10 signaling would, therefore, be the presence of
another CXCL10 binding receptor. A novel functional receptor
with unknown identity that binds CXCL10 has been identified
recently, with abundant levels in epithelial and endothelial cells
(Soejima and Rollins, 2001). Unlike CXCR3, this receptor does
not bind CXCL9 or CXCL11, which would support our findings
that CXCL9 and CXCL11 have no effect on the b cells in contrast
to CXCL10. Possible candidates were a variety of seven-
transmembrane-spanning G protein-coupled receptors with se-
quence motifs shared by chemokine receptors. Of these orphan
receptors, we have tested GPR1, which was highly expressed
in islets but failed to bind CXCL10. Another candidate, APJ
(Marchese et al., 1994), was only marginally present in human is-
lets (data not shown). CXCR3 ligands have been shown before to
bind to CCR3, the receptor for eotaxin and several CC chemo-
kines, but lack agonistic effects (Booth et al., 2002; Loetscher
et al., 2001). CCR5 is highly upregulated by TNF-a and IFN-g,
together with upregulation of CXCL10 (Croitoru-Lamoury et al.,
2003). Both CCR3 and CCR5 were expressed in islets. Though
CCR3 bound to CXCL10 to a limited extent, CCR5 did not.CeInterestingly, we observed activation of CXCL10 mRNA upon
CXCL10 exposure, and such CXCL10 upregulation is an impor-
tant downstream event of Toll-like receptor 4 (TLR4) activation
(Giarratana et al., 2004; Hoshino et al., 2002; Selvarajoo, 2006).
We confirmed TLR4 expression (Giarratana et al., 2004; Vives-
Pi et al., 2003) in human islets, tested its binding capacity to
CXCL10, and found CXCL10 as a ligand for TLR4. We have
excluded a possible contamination of the recombinant protein
with microbial products by preincubation of CXCL10 with
polymyxin B, which blocks LPS activity. This had no effect on
the CXCL10 actions. In contrast, preincubation of CXCL10 with
a neutralizing CXCL10 antibody prevented its effects.
Signal transduction downstream of TLR4 is another mecha-
nism that induces Akt activation. Other ligands of TLR4; LPS
(Li et al., 2003) and lauric acid (Lee et al., 2003) showed this,
resulting in NFkB activation and inflammation. TLR4 depletion
prolongs islet graft survival of pancreatic islets after transplanta-
tion (Goldberg et al., 2007). Importantly, nonendotoxine ligands
of TLR4 have been identified; Shi et al. show that free fatty acids
induce TLR4 upregulation and activation in adipocytes and
macrophages and induce inflammation and trigger insulin resis-
tance (Shi et al., 2006). A possible explanation for the increase in
CXCL10 in obese individuals could be that elevated circulating
levels of free fatty acids (Wilding, 2007), which bind to TLR4,
would consequently result in increased production of CXCL10.
A loss-of-function mutation in TLR4 prevents diet-induced obe-
sity and insulin resistance (Tsukumo et al., 2007). Furthermore,
a TLR4 gene polymorphism in humans is associated with
reduced CRP levels and a decreased risk of coronary heart
disease and diabetes (Kolek et al., 2004). These earlier studies
and our new observations suggest that TLR4 signaling plays
an important role in diabetes and insulin resistance.
The present study provides further evidence that chemokines,
in addition to other proinflammatory factors, directly trigger b cell
destruction and contribute to the pathophysiology of T2DM.
CXCL10, which is expressed relatively early in diabetes develop-
ment as seen in the NOD mouse and in pancreata from obese
nondiabetic individuals, may serve as amarker for b cell destruc-
tion, but more studies from different cohorts are required to
confirm this hypothesis. Our data suggest a potential mecha-
nism for the switch from proliferation into apoptosis in b cells.
Using anti-inflammatory targets of the TLR4-signaling pathway
will be of high importance to rescue the b cell from inflamma-
tion-induced self-destruction and to preserve b cell function
and mass.
EXPERIMENTAL PROCEDURES
Details on procedures, animals, antibodies, and primers used are given in the
Supplemental Data.
Animals
C57BL/6J and TLR4 knockout mice (C57BL/10ScCr) were obtained from
Jackson Laboratory (Bar Harbor, ME). Homozygous CXCR3 on a C57BL/6J
background were kindly provided by Dr. Craig Gerard (Perlmutter Laboratory,
Children’s Hospital and Harvard Medical School, Boston, MA). Animal exper-
iments were conducted according to the protocols approved by the University
of California Los Angeles Chancellor’s Animal Research Committee and by the
Bremen Senate in agreement with the National Institutes of Health animal care
guidelines and x8 of the German animal protection law.ll Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier Inc. 135
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Human islets were isolated from pancreata of 11 healthy organ donors and 3
with T2DM as described previously (Oberholzer et al., 2000). Human islets
from three isolations were purified into single b cells and cultured as described
(Meyer et al., 1998). Mouse islets were isolated by bile duct perfusion and col-
lagenase digestion as described (Maedler et al., 2001).
Measurement of CXCL10 Release
CXCL10 secretion into culture media of isolated islets from healthy and
organ donors with T2DM was assessed by a Human Cytokine/Chemokine
LINCOplex Kit (Linco Research, Inc., St. Charles, MO) according to the
manufacturer’s instructions.
Measurement of Changes in Intracellular Ca2+ Concentration
INS-1 cells were seeded on Fluoro dishes (WPI, Sarasota, FL) and cultured
overnight in RPMI 1640 medium containing 3 mM glucose without FCS. Cells
were loaded with 2.5 mM Fluo-3 AM by incubation for 30 min in KRB buffer.
Immunohistochemistry
Human islet sections were prepared as described before (Maedler et al.,
2002b). Human pancreatic tissue was obtained at autopsy from nondiabetic
subjects and from patients with T2DM (all with documented fasting plasma
glucose > 145 mg/dl; see Table S1). A pancreas biopsy was obtained from
an 89-year-old newly T1DM-diagnosed patient (with random blood glucose
of 349 mg/dl; details described recently [Meier et al., 2006]).
Western Blot Analysis
Islet lysates were prepared as described previously (Maedler et al., 2006).
Protein Pull-Down Assay
Dynabeads M-270 Epoxy (Invitrogen) were coated with recombinant human
CXCL10 (R&D Systems Inc., Minneapolis, MN). After washing, human islet
cell lysates were added to the beads and incubated for 1 hr. Bound proteins
were eluted in Laemmli buffer for SDS-PAGE. Whole-cell lysates from cultured
islets, eluted samples, and flowthrough were electrically transferred to PVDF
membranes.
Chemokine-Binding Assay
Binding assays were performed using RAW264.7 cells (constitutively express-
ing TLR4 [Fang et al., 2004]) or HEK293 cells (not expressing TLR4 [Visintin
et al., 2001]) transfected with or without the combination of pFLAG-TLR4,
pFLAG-CD14 (kindly provided by Dr. Kirschning, TU Munich [Dziarski et al.,
2001]), and pDUO-hMD2/TLR4A (kindly provided by Dr. Clett Erridge, Institute
of Biomedical and Life Sciences, University of Glasgow [Erridge et al., 2008])
receptor expression plasmids using a standard policationic lipid reagent
protocol.
RNA Extraction and Quantitative Reverse Transcription-PCR
Total RNAwas isolated from the cultured islets and analyzed as described pre-
viously (Maedler et al., 2006). Primer sequences are published in the Supple-
mental Data.
Plasmid Overexpression and Small Interfering RNA
siRNA-Lipofectamine2000 complexes were prepared as described before
(Shu et al., 2008) (Liptofectamine2000; invitrogen) using 50 nM siRNA to
TLR4 (Stealth Select RNAi, invitrogen) and scramble siRNA (Ambion, Austin,
TE) and added to the islet culture. Plasmid overexpression of TLR4 (kindly pro-
vided by Dr. Carsten Kirschning) was performed as described before (Maedler
et al., 2002a).
Glucose-Stimulated Insulin Secretion, Intraperitoneal Glucose,
and Insulin Tolerance Tests
Tests were performed as described previously in detail (Sauter et al., 2008).
Statistical Analysis
Samples were evaluated in a randomized manner by a single investigator
(F.T.S. blinded to the treatment conditions). Data were analyzed by paired,136 Cell Metabolism 9, 125–139, February 4, 2009 ª2009 Elsevier InStudent’s t test or by analysis of variance with a Bonferroni correction for
multiple group comparisons.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, one
table, and one figure and can be found with this article online at http://www.
cell.com/cell-metabolism/S1550-4131(09)00004-7.
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